IP Library Granted Patent US 9,447,414
Granted Patent B2
US 9,447,414 · App. 14/741,064 · Granted Sep 20, 2016

Methods and compositions involving miRNA and miRNA inhibitor molecules

Inventors: David Brown (Austin, TX); Lance Ford (Austin, TX); Angie Cheng (Austin, TX); Rich Jarvis (Austin, TX); Mike Byrom (Austin, TX); Dmitriy Ovcharenko (Austin, TX); Eric Devroe (Pflugerville, TX); Kevin Kelnar (Kyle, TX)
Assignee: ASURAGEN, INC.
C12N15/113A61K9/127A61K31/7088A61K31/713A61K31/7105A61K45/06A61N5/10C12N15/111C12N15/1136C12Q1/68C12N2310/14C12N2310/141C12N2310/312C12N2310/322C12N2310/33C12N2310/344C12N2310/35C12N2310/351C12N2310/3527C12N2310/3535C12N2310/533C12N2320/12C12N2320/30C12N2320/50C12N2330/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,414
App. No.
14/741,064
Granted
Sep 20, 2016
Kind
B2
Abstract

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Claims (6)

1. A method of reducing tumor cell viability in an individual in need thereof, wherein the tumor is a lung cancer, comprising: administering to the individual a therapeutically effective amount of a composition comprising: a synthetic miRNA comprising:

a. an active strand having the sequence of SEQ ID NO: 58, and

b. a separate complementary strand that is at least 60% complementary to the active strand and has a 5′-terminal nucleotide that is chemically modified to comprise a lower alkylamine group, and

wherein the synthetic miRNA is encapsulated in a liposome.

2. The method of claim 1 wherein the composition is administered in combination with a first anticancer agent, radiotherapy, or combinations thereof.

3. The method of claim 2 , wherein the composition is administered in combination with a second anticancer agent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: BROWN, DAVID; FORD, LANCE; CHENG, ANGIE; JARVIS, RICH; BYROM, MIKE; OVCHARENKO, DMITRIY; DEVROE, ERIC; KELNAR, KEVIN
To: AMBION, INC.
Reel/Frame 035973/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: AMBION, INC.
To: APPLERA CORPORATION
Reel/Frame 035973/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: APPLERA CORPORATION
To: ASURAGEN, INC.
Reel/Frame 035973/0380 →
Continuity (8)
Continuation 14712591 · May 14, 2015
Continuation 13887008 · May 3, 2013
Continuation 13299255 · Nov 17, 2011
Division 11273640 · Nov 14, 2005
Provisional Application 60683736 · May 23, 2005
Provisional Application 60649634 · Feb 3, 2005
Provisional Application 60627171 · Nov 12, 2004
Related Publication 20150352046A1 · Dec 10, 2015